NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, in Fort Lauderdale, Florida. The presentation offers investors a direct look at a pipeline that has moved into late-stage clinical testing, a milestone that could reshape treatment options for several high-consequence viral diseases.
The centerpiece of the company's strategy is NV-387, a broad-spectrum antiviral currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. These trials are significant because Ebola and Mpox outbreaks disproportionately affect regions with limited healthcare infrastructure, and a broad-spectrum antiviral could provide a rapidly deployable countermeasure. If successful, NV-387 could become a frontline therapy for multiple viral threats, reducing the need for separate, virus-specific treatments.
Beyond these indications, NanoViricides is planning clinical trials of NV-387 for measles, for which the drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. These designations are important because they provide incentives such as market exclusivity and priority review, potentially accelerating development. Measles, though vaccine-preventable, still causes outbreaks worldwide, and a targeted antiviral could be critical for unvaccinated or immunocompromised individuals.
The company's pipeline also includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS. The breadth of this pipeline underscores NanoViricides' platform approach, which is based on the nanoviricide technology licensed from TheraCour Pharma. This technology aims to create special purpose nanomaterials that attack viruses by mimicking the cell surface receptors they bind to, offering a potential new mechanism of action.
For investors, the NIBA presentation is a chance to assess the company's progress as it advances NV-387 into Phase II human clinical trials. The full press release is available at https://ibn.fm/vQCM4, and additional information about the company can be found at www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication and corporate communications solutions, including social media distribution to millions of followers. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
The implications of NanoViricides' progress extend beyond a single conference appearance. If NV-387 proves effective in its ongoing trials, it could offer a new paradigm for antiviral therapy, where a single drug addresses multiple viruses. This would be particularly valuable in outbreak settings, where rapid deployment of a broad-spectrum agent could save lives and contain spread. However, the company acknowledges that drug development is lengthy and requires substantial capital, and there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development. Investors will be watching closely as the company advances its clinical programs.
